Business
Manganese X Subsidiary and JV Partner PureBiotic Air Inc. Provide Virginia State University Testing Update on Biofilm Deconstruction of Pathogens Including COVID-19
Montreal, Quebec--(Newsfile Corp. - May 18, 2021) - Manganese X Energy Corp. (TSXV: MN) (FSE:...
About this update from Manganese X Energy Corp.
[{"type":"text","content":"Manganese X Subsidiary and JV Partner PureBiotic Air Inc. Provide Virginia State University Testing Update on Biofilm Deconstruction of Pathogens Including COVID-19Montreal, Quebec--(Newsfile Corp. - May 18, 2021) - Manganese X Energy Corp. (TSXV: MN) (FSE: 9SC2) (OTCQB: MNXXF) (\"Manganese X\", \"MN\" or the \"Company\") is pleased to announce that its wholly owned subsidiary, Disruptive Battery Corp. (\"DBC\"), in conjunction with its US JV Partner, PureBiotic AIR, Inc. (\"PureBiotic\"), has received additional positive preliminary results from its ongoing research study with Virginia State University (VSU). Early results indicate that PureBiotic AIR Mist Solutions can potentially be effective in causing the deconstruction of biofilm, calculated by the Center for Disease Control (CDC) to be responsible for 80% of all infections, thereby reducing the risk of infection from pathogenic bacteria and viruses, including SARS-CoV-2 virus, cause of the COVID-19 pandemic. Manganese X Energy Corp. CEO Martin Kepman said, \"There were some delays caused by the COVID-19 restrictions in accessing VSU testing facilities, as well as staff availability. We have now been notified that testing will resume on a regular basis with their staff as long as there are no additional COVID-19 interruptions.\"The initial VSU testing also included the successful production of the biofilm growth required to advance its research and testing of DBC's PureBiotic AIR HVAC Delivery System for the mitigation of infection risks, including COVID-19 and other contaminants. Applications of the PureBiotic AIR Mist Solutions are currently being tested on the biofilm grown from specific pathogens selected from the common human environment. The company's ultimate goal is to create a product for FDA certification. With test results now indicating the possibility that the PureBiotic AIR Mist Solutions can be effective in causing the deconstruction of the biofilm, the VSU research team will continue its study to document the reduction in infection risk. This component of the research will cover a wide range of infection types, addressing some of the current concerns due to the COVID pandemic and its variants, as well as that of the extensive range of Hospital Acquired Infections (HAI's). Background Information on PureBiotic AIR Mist SolutionsThis research studies the possi...